Although much of the focus and excitement of anti-PD-1 antibody therapy has been in the field of oncology, in which it has been demonstrated to be highly effective in inducing remissions in patients with a variety of malignancies [14,15], anti-PD-1 has also shown significant success in infectious disease. The gene discussed is PDCD1; the disease is infectious disease.